This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Ozaki, Y Articles by Nakamura, S Search for Related Content PubMed PubMed Citation Articles by Ozaki, Y Articles by Nakamura, S

 Previous Article  |  Next Article 

Infect Immun. 1987 June; 55(6): 1436-1440

Enhanced resistance of mice to bacterial infection induced by recombinant human interleukin-1a.

ABSTRACT

The effect of recombinant human interleukin-1a on the survival rate of Std-ddY male mice systemically infected with Pseudomonas aeruginosa 12 or Klebsiella pneumoniae P-5709 was evaluated. In P. aeruginosa infection, interleukin-1a given intramuscularly twice, 3 days and 1 day before inoculation of bacteria, most effectively protected animals from death due to infection. The effect was dose dependent, with a maximum survival rate of 92.5% at 10 micrograms per mouse, while only 8.3% of the control group survived until the end of the observation period. The 50% effective dose of interleukin-1a was 0.261 microgram per mouse. In K. pneumoniae infection, interleukin-1a given intramuscularly twice, simultaneously with and 1 day after the inoculation of bacteria, was most effective. The protective effect of interleukin-1a was again dose dependent and was generally more marked than in P. aeruginosa infection. The 50% effective dose was 0.034 microgram per mouse. In both infections, there was no significant increase in the survival rates of animals injected with human albumin or heat-inactivated interleukin-1a. These observations raise the possibility that human interleukin-1a could serve as a therapeutic tool for patients with bacterial infections.

This article has been cited by other articles:

• Hochepied, T., Van Molle, W., Berger, F. G., Baumann, H., Libert, C. (2000). Involvement of the Acute Phase Protein alpha 1-Acid Glycoprotein in Nonspecific Resistance to a Lethal Gram-negative Infection. J. Biol. Chem. 275: 14903-14909 [Abstract] [Full Text]  
• Laine, V. J. O., Grass, D. S., Nevalainen, T. J. (1999). Protection by Group II Phospholipase A2 Against Staphylococcus aureus. J. Immunol. 162: 7402-7408 [Abstract] [Full Text]  
• VAN DER MEER, J. W.M., VOGELS, M. T.E., NETEA, M. G., KULLBERG, B. J. (1998). Proinflammatory Cytokines and Treatment of Disease. Ann. N. Y. Acad. Sci. 856: 243-251 [Abstract] [Full Text]  
• Greisman, S.E., Johnston, C.A. (1997). Review: Evidence against the hypothesis that antibodies to the inner core of lipopolysaccharides in antisera raised by immunization with enterobacterial deep-rough mutants confer broad-spectrum protection during Gram-negative bacterial sepsis. Innate Immunity 4: 123-153 [Abstract]  
• Veltri, S., Smith, J. W. II (1996). Interleukin 1 Trials in Cancer Patients: A Review of the Toxicity, Antitumor and Hematopoietic Effects. The Oncologist 1: 190-200 [Abstract] [Full Text]  
• Veltri, S, Smith, J. 2nd (1996). Interleukin 1 trials in cancer patients: a review of the toxicity, antitumor and hematopoietic effects. Stem Cells 14: 164-176 [Abstract]